stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Book value per share
Legend Biotech Corporation Sponsored ADR's book value per share at the end of fiscal 2025 was 5.4×, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was 6.6×. Over the past ten years it has ranged from −1.2× (fiscal 2019) to 7.1× (fiscal 2023); the current reading is higher than 67% of that period. Legend Biotech Corporation Sponsored ADR ranks 121st of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 5.4× | (4.47%) |
| FY2024 | 5.7× | (19.92%) |
| FY2023 | 7.1× | 51.85% |
| FY2022 | 4.7× | (13.94%) |
| FY2021 | 5.4× | 129.25% |
| FY2020 | 2.4× | — |
| FY2019 | −1.2× | — |
| FY2018 | 0.1× | 13.07% |
| FY2017 | 0.1× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 6.6× | 25.77% |
| Mar 2026 | 5.2× | (3.84%) |
| Dec 2025 | 5.4× | (0.74%) |
| Sep 2025 | 5.5× | (2.60%) |
| 27 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| DNTH Dianthus Therapeutics, Inc. compare | 21.6× |
| CRSP CRISPR Therapeutics AG compare | 17.0× |
| EWTX Edgewise Therapeutics, Inc. compare | 15.0× |
| DFTX Definium Therapeutics, Inc. compare | 8.3× |
| LEGN Legend Biotech Corporation Sponsored ADR | 6.6× |
| RLAY Relay Therapeutics, Inc. compare | 3.7× |
| COGT Cogent Biosciences, Inc. compare | 3.1× |
| ERAS Erasca, Inc. compare | 1.2× |
| TVTX Travere Therapeutics, Inc. compare | 0.2× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on LEGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement